REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System

Inclusion Criteria: * Subject is ≥70 years of age * Subject has documented calcific native aortic valve stenosis * Subject has a documented aortic annulus size between ≥19 and ≤27 mm based on pre-procedure diagnostic imaging * Symptomatic aortic valve stenosis with NYHA Functional Class ≥ II * Subject is considered high risk for surgical valve replacement * Heart team assessment that the subject is likely to benefit from valve replacement. * Subject (or legal representative) understands the study requirements and the treatment procedures, and provides written informed consent. * Subject, family member, and/or legal representative agree(s) and subject is capable of returning to the study hospital for all required scheduled follow up visits. Exclusion Criteria: * Subject has a congenital unicuspid or bicuspid aortic valve. * Subject with an acute myocardial infarction within 30 days of the index procedure * Subject has had a cerebrovascular accident or transient ischemic attack within the past 6 months, or has any permanent neurologic defect prior to study enrollment. * Subject is on dialysis or has serum creatinine level \>3.0 mg/dL or 265 µmol/L. * Subject has a pre-existing prosthetic heart valve (aortic or mitral) or a prosthetic ring in any position. * subject cannot have more than moderate mitral, aortic or tricuspid regurgitation * Subject has a need for emergency surgery for any reason. * Subject has a history of endocarditis within 12 months of index procedure or evidence of an active systemic infection or sepsis. * Subject has echocardiographic evidence of intra-cardiac mass, thrombus or vegetation. * Subject has low Hgb, platelet count or \>700,000 cells/mm3, or low white blood cell count. * Subject requires chronic anticoagulation therapy and cannot tolerate concomitant therapy with either aspirin or clopidogrel/ticlopidine * Subject has active peptic ulcer disease or gastrointestinal bleed within the past 3 months, other bleeding diathesis or coagulopathy or will refuse transfusions. * Subject has known hypersensitivity to contrast agents that cannot be adequately pre-medicated, or has known hypersensitivity to aspirin, all thienopyridines, heparin, nickel, tantalum, titanium, or polyurethanes. * Subject has a life expectancy of less than 12 months due to non-cardiac, co-morbid conditions based on the assessment of the investigator at the time of enrollment. * Subject has hypertrophic obstructive cardiomyopathy. * Subject has any therapeutic invasive cardiac procedure within 30 days prior to the index procedure (except for pacemaker implantation which is allowed). * Subject has untreated coronary artery disease. * Subject has documented left ventricular ejection fraction \<30%. * Subject is in cardiogenic shock or has hemodynamic instability requiring inotropic support or mechanical support devices. * Subject has severe peripheral vascular disease or symptomatic carotid or vertebral disease. * Narrow Femoral artery lumen precludes the use of either Lotus device size, or severe iliofemoral tortuosity or calcification that would prevent safe placement of the introducer sheath. * Current problems with substance abuse (e.g., alcohol, etc.). * Subject is participating in another investigational drug or device study that has not reached its primary endpoint. * Patient has preexisting untreated conduction system disorder that requires new pacemaker implantation.